Kaleido: KB109 Shows Favorable Safety, Tolerability Profile In Non-IND Study

Kaleido Biosciences, Inc. (KLDO) reported positive results from a non-IND study of KB109 in patients with mild-to-moderate COVID-19. KB109 demonstrated an overall favorable safety and tolerability profile with no unexpected treatment-related adverse events.

The company said the data showed a reduction in overall COVID-19 related healthcare utilization. The study also showed a significant reduction in recovery time for patients age 45 and older or with one or more comorbidity who received KB109 plus self-supportive care as compared to patients receiving self-supportive care alone.

Kaleido said it plans to file an Investigational New Drug application, with the goal of advancing KB109 directly into a pivotal registration program.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cove Appliance Inc. is recalling about 42,000 units of built-in dishwashers citing fire risk, the U.S. Consumer Product Safety Commission said. The recall involves Cove Appliance 24-inch built-in residential dishwashers model numbers DW2450 and DW2450WS. The recalled dishwashers have serial numbers 20000100 through 20044445. Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets.
Follow RTT